索磷布韦/维帕他韦/伏西瑞韦在DAA经治患者中的挽救治疗:加拿大前瞻性登记研究结果
该研究基于加拿大前瞻性登记(CANUHC,17个中心),评估索磷布韦/维帕他韦/伏西瑞韦(SVV)作为挽救治疗在既往DAA治疗失败后的慢性HCV感染患者中的疗效。共纳入128例患者,总体SVR率为96%(123/128);
要点
- SVV挽救治疗总体SVR率96%,与III期临床试验报告相似。
- SVV失败者至少具备以下2项因素:基因3型、肝硬化、肝移植史、既往索磷布韦/维帕他韦暴露和/或复杂耐药谱。
核心结论
- SVV作为既往DAA治疗失败后的挽救治疗具有高度有效性,总体SVR率达96%。
- SVV治疗失败者至少具备基因3型、肝硬化、肝移植史、既往索磷布韦/维帕他韦暴露和/或复杂耐药谱中的2项因素。
研究设计与样本
- 前瞻性加拿大登记研究(CANUHC),覆盖加拿大17个中心。
- 纳入128例既往DAA治疗未获SVR后接受SVV治疗的HCV感染患者。
- 评估SVV治疗后SVR率及与失败相关的因素,并分析RAS检测和利巴韦林使用的效用。
主要发现
- 128例患者中80%为男性,中位年龄57.5岁(范围31-86),44%有肝硬化,17例为肝移植后。
- 一线方案包括索磷布韦/维帕他韦(27.3%)、索磷布韦/来迪派韦(26.5%)、格卡瑞韦/哌仑他韦(12.5%)和其他(33.5%)。
- 26例患者在SVV基础上加用利巴韦林,原因包括既往索磷布韦/维帕他韦使用(n=8)、复杂RAS谱(n=16)和/或肝硬化(n=9)。
关键数值与推荐
- SVV被推荐为多数患者的一线再治疗方案。
- 总体SVR率96%(123/128)。
- SVV失败者至少具备以下2项因素:基因3型、肝硬化、肝移植史、既往索磷布韦/维帕他韦暴露和/或复杂耐药谱。
临床怎么用
- SVV可作为既往DAA治疗失败后多数患者的有效挽救治疗方案。
- 对既往索磷布韦/维帕他韦失败者,需关注较低SVR率,考虑加用利巴韦林或基于RAS检测个体化治疗。
- 存在基因3型、肝硬化、肝移植史、既往索磷布韦/维帕他韦暴露和/或复杂耐药谱中至少2项者,SVV失败风险较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the current highly effective therapies with direct-acting antiviral agents (DAAs), some patients with chronic hepatitis C virus (HCV) infection still do not achieve sustained virological response (SVR) and require retreatment. Sofosbuvir/velpatasvir/voxilaprevir (SVV) is recommended as the first-line retreatment option for most patients. The aim of this study was to evaluate the efficacy of SVV as salvage therapy after at least one course of DAA. METHODS: Data were collected on all HCV-infected patients who failed DAAs and were prescribed SVV from a prospective Canadian registry (CANUHC) including 17 sites across Canada. Factors associated with failure to achieve SVR with SVV therapy and the utility of RAS testing and ribavirin use were evaluated. RESULTS: A total of 128 patients received SVV after non-SVR with DAA treatment: 80% male, median age 57.5 (31-86), 44% cirrhotic, and 17 patients post liver transplant. First line regimens included: sofosbuvir/velpatasvir (27.3%), sofosbuvir/ledipasvir (26.5%), grazoprevir/elbasvir (12.5%), other (33.5%). Ribavirin was added to SVV in 26 patients due to past sofosbuvir/velpatasvir use (n = 8), complex resistance associated substitution profiles (n = 16) and/or cirrhosis (n = 9). Overall SVR rate was 96% (123/128). Of 35 patients who previously failed sofosbuvir/velpatasvir, 31 (88.5%) achieved SVR compared to 92 of 93 (99%) among those receiving any other regimen (P = .01). CONCLUSIONS: Similar to reports from phase 3 clinical trials, SVV proved highly effective as salvage therapy for patients who failed a previous DAA therapy. Those who failed SVV had at least 2 of the following factors: genotype 3, presence of cirrhosis, past liver transplantation, past exposure to sofosbuvir/velpatasvir and/or complex resistance profiles.
引用
- Onofrio FQ, Cooper C, Borgia SM, et al. Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry. Clin Infect Dis. 2021. PMID: 33677545. doi:10.1093/cid/ciaa1510
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。